Eisai Co., Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ESAIY Over the counter 2834 www.eisai.co.jp

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eisai Co., Ltd.

Why the CNS boom owes its success to breakthroughs in neurological pathologies - Sep 8th, 2026 12:13 pm
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients - Sep 3rd, 2026 5:06 am
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China - Sep 2nd, 2026 10:00 pm
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease - Aug 31st, 2026 5:30 pm
Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab) - Aug 31st, 2026 12:04 pm
Global Indocyanine Green Market to Reach USD 380 Million by 2031, Growing at a 13.26% CAGR - Aug 31st, 2026 9:19 am
Eisai (TSE:4523) Launches At Home LEQEMBI, Is The Stock 8% Overvalued? - Aug 30th, 2026 4:19 pm
Sophus IT Solutions Named an OpenAI Select Partner, Expanding Production AI Deployments and Geospatial Intelligence Solutions - Aug 27th, 2026 6:55 am
BioArctic: Interim Report for the period April - June 2026 - Aug 26th, 2026 12:46 am
Leqembi Iqlik® for initiation treatment launched in the US - Aug 24th, 2026 6:43 am
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease - Aug 24th, 2026 6:00 am
Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More - Aug 7th, 2026 3:37 am